Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
| Autor: | Jiahui Chen, Rui Wang, Nancy Benovich Gilby, Guo-Wei Wei |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
COVID-19 Vaccines
SARS-CoV-2 Omicron infectivity General Chemical Engineering COVID-19 General Chemistry Library and Information Sciences Antibodies Monoclonal Humanized Quantitative Biology - Quantitative Methods Antibodies Neutralizing Article United States Computer Science Applications Artificial Intelligence FOS: Biological sciences Spike Glycoprotein Coronavirus Humans vaccine breakthrough antibody-resistance Quantitative Methods (q-bio.QM) |
| Zdroj: | ArXiv article-version (number) 1 article-version (status) pre Journal of Chemical Information and Modeling |
| ISSN: | 1549-960X 1549-9596 |
| DOI: | 10.1021/acs.jcim.1c01451 |
| Popis: | The latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron (B.1.1.529) has ushered panic responses around the world due to its contagious and vaccine escape mutations. The essential infectivity and antibody resistance of the SARS-CoV-2 variant are determined by its mutations on the spike (S) protein receptor-binding domain (RBD). However, a complete experimental evaluation of Omicron might take weeks or even months. Here, we present a comprehensive quantitative analysis of Omicron’s infectivity, vaccine breakthrough, and antibody resistance. An artificial intelligence (AI) model, which has been trained with tens of thousands of experimental data and extensively validated by experimental results on SARS-CoV-2, reveals that Omicron may be over 10 times more contagious than the original virus or about 2.8 times as infectious as the Delta variant. On the basis of 185 three-dimensional (3D) structures of antibody–RBD complexes, we unveil that Omicron may have an 88% likelihood to escape current vaccines. The U.S. Food and Drug Administration (FDA)-approved monoclonal antibodies (mAbs) from Eli Lilly may be seriously compromised. Omicron may also diminish the efficacy of mAbs from AstraZeneca, Regeneron mAb cocktail, Celltrion, and Rockefeller University. However, its impacts on GlaxoSmithKline’s sotrovimab appear to be mild. Our work calls for new strategies to develop the next generation mutation-proof SARS-CoV-2 vaccines and antibodies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|